Propagation of α-synuclein pathology: models, mechanisms and future goals Authors: Aryeh Zolin, Sarah A. Weber, Yan Xin Xie, Jacqueline Burré Published: 2026 ABSTRACT Misfolding and aggregation of α-synuclein underlies several progressive neurodegenerative disorders for which there are no disease-modifying therapies, most notably Parkinson’s disease. α-Synuclein pathology can be transmitted across adjacent cells, and this prion-like property is thought to underlie disease progression. Here, we review what is known about how α-synuclein pathology spreads between cells and evaluate the different model systems used to address this question, including cultured cells, invertebrates, rodents, and non-human primates. Cellular systems have revealed potential molecular mechanisms underlying α-synuclein release and uptake. However, they lack the physiological complexity needed to recapitulate circuit-level spread. Invertebrate models overcome this limitation but lack endogenous α-synuclein. Rodents are the most frequently used model and have provided key insights into the anatomical progression of pathology. Inoculation of pathogenic α-synuclein into targeted regions initiates sequential involvement of connected structures, revealing principles such as directionality, selective vulnerability, and synaptic connectivity to pathology propagation. Yet, they incompletely model the slow time course and multisystem involvement seen in patients. Non-human primate models offer a closer representation of human neuroanatomy, synaptic organization, and lifespan. These models capture features such as long-distance propagation, dopaminergic neuron degeneration, and the emergence of motor symptoms over extended periods. Their value lies in bridging molecular mechanisms with organism-level dysfunction, but they face technical and practical limitations. Together, these complementary systems have provided insight into how α-synuclein pathology spreads across the brain. In reviewing the literature, we find there is little consensus and no cogent understanding of the mechanisms underlying release and uptake of pathologic α-synuclein aggregates. We propose a need for a deeper understanding of how α-synuclein aggregation spreads. This requires integrating insights across cellular, rodent, and primate models and leveraging the strengths of each system to enable the identification of targetable mechanisms of transmission and guide the development of disease-modifying therapies.Graphical Abstract Background Cytotoxic aggregates composed mainly of α-synuclein (αSyn) are the pathological hallmark of synucleinopathies, a group of neurodegenerative disorders that includes Parkinson’s disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) [1–12]. Mounting evidence posits that αSyn possesses prion-like properties: misfolded and aggregated αSyn is transmitted from one cell to another, where it acts as a seed that triggers the dysfunction, misfolding, and aggregation of local αSyn [13–28]. The resultant spread of pathology through interconnected neural tissues is thought to underlie disease progression and is therefore of diagnostic interest and an exciting therapeutic target [29–41]. However, there is limited consensus as to the molecular mechanisms underlying trans-cellular propagation of αSyn pathology, with many competing hypotheses, impeding the development of effective treatments. We propose a multi-step framework for understanding the prion-like spread of αSyn pathology (Fig. 1). Inoculation is the initial insult that causes αSyn dysfunction, misfolding, and aggregation. In human synucleinopathies, the disease process is thought to begin intracellularly with changes in αSyn conformation [1, 7, 36, 42, 43]. However, in several disease models, αSyn aggregates (inoculum) are introduced into extracellular spaces and must be internalized before they can then corrupt endogenous αSyn, corresponding to the steps of primary uptake and primary seeding. This is followed by primary release, and then secondary uptake, seeding, and release which do not require the initial inoculum, but rather rely on corrupted endogenous αSyn. Secondary, tertiary, and further propagation are therefore the most physiologically relevant and desirable to study.Fig. 1Framework for studying and understanding cell-to-cell propagation of αSyn pathology. Experimental means to induce αSyn aggregation (inoculation and primary uptake) include transfection, viral transduction, exposure to αSyn fragments, monomers, oligomers, or PFFs, or incubation or injection of human tissue (CSF or homogenates from post-mortem brain samples). αSyn oligomers and PFFs are generated from recombinant proteins expressed in bacteria, harvested from cultured cell media, or derived from human tissue. Primary release and secondary uptake represent the secretion and internalization of corrupted native αSyn from inoculated cells and to adjacent cells, respectively. Secondary release and tertiary uptake represent the continued propagation of αSyn pathology between cells. Inoculation is a fundamentally artificial process that is definitionally distinct from actual disease pathogenesis, whereas subsequent steps in the pathway are more likely to reflect disease-relevant processes as they involve actual cell-to-cell transmission and natively expressed αSyn Framework for studying and understanding cell-to-cell propagation of αSyn pathology. Experimental means to induce αSyn aggregation (inoculation and primary uptake) include transfection, viral transduction, exposure to αSyn fragments, monomers, oligomers, or PFFs, or incubation or injection of human tissue (CSF or homogenates from post-mortem brain samples). αSyn oligomers and PFFs are generated from recombinant proteins expressed in bacteria, harvested from cultured cell media, or derived from human tissue. Primary release and secondary uptake represent the secretion and internalization of corrupted native αSyn from inoculated cells and to adjacent cells, respectively. Secondary release and tertiary uptake represent the continued propagation of αSyn pathology between cells. Inoculation is a fundamentally artificial process that is definitionally distinct from actual disease pathogenesis, whereas subsequent steps in the pathway are more likely to reflect disease-relevant processes as they involve actual cell-to-cell transmission and natively expressed αSyn In actual disease, initial αSyn dysfunction and aggregation may be focal or multifocal, and result from a complex interplay between environmental exposure (including chemical and infectious agents) [44–47], genetic background [46, 48], neuroanatomic location [33], microenvironment (including interactions with glial, immune, epithelial, and vascular cells and extracellular milieu) [49–53], cellular properties [14, 35, 54–56] and molecular composition [21, 34, 50, 57–76]. Excepting environmental insults, the above factors may continue to differentially impact pathological transmission, which may also be affected by the nature of the interaction between the two participating cells. The mechanisms underlying transmission may be different across neuropil and cell-type. Fully characterizing and defining the mechanisms of αSyn pathology’s prion-like propagation is therefore a daunting, but vital task. Our current understanding of the transcellular propagation of αSyn aggregation comes from observational studies of post-mortem human tissue (extensively reviewed here [23, 77–79]) as well as a variety of studies in model systems. Here, we describe and assess strengths and weaknesses of the different models used to study these processes and review what is known about each step. Our goal is to highlight how ongoing and future work can provide meaningful, mechanistic insight into the cell-to-cell transmission of αSyn pathology and thereby enable the development of therapeutic strategies that are applicable to human disease. Cellular models In cellulo experimental systems The ability of various conformations of αSyn to be taken up from surrounding media, to be transferred between cells, and to induce intracellular αSyn misfolding and aggregation has been demonstrated across an array of cultured cells, including rat adrenal pheochromocytoma cells (PC12) [80], Chinese hamster ovary cells (CHO) [81, 82], mouse neuroblastoma cells (Neuro-2a) [80, 83], mouse catecholaminergic neuron-like cells (CAD) [84, 85], HeLa cells [86], human embryonic kidney 293 cells (HEK293) [80, 86], human neuroblastoma cells (SH-SY5Y) [86, 87], human neuroglioma cells (H4) [88–90], human embryonic neuronal precursor cells (e.g., LUHMES) [25, 89], human melanoma cells (SKMel5) [80], and human myelogenous leukemic cells [91, 92], as well as primary rodent neurons [93, 94] and primary rodent glia [95, 96]. Neurons and glia derived from induced pluripotent stem cells (iPSC) are an emerging in vitro model to study the transmission of αSyn pathology. iPSC-derived organoids, neurons, or glia from individuals with synucleinopathies or with genetic predispositions produce and release αSyn that can be collected, concentrated, and treated, to generate αSyn fibrils, which are in turn capable of corrupting native αSyn in wild-type (WT) iPSC-derived tissues [78, 97–100]. For example, dopaminergic neurons derived from individuals carrying glucocerebrosidase (GBA) mutations release αSyn monomers and higher order multimeric configurations into the extracellular space [55, 101], astrocytes derived from individuals with the leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) G2019S mutation transmit αSyn to co-cultured WT dopaminergic neurons [102], iPSC-derived microglia with an SNCA-triplication release high levels of αSyn into the extracellular space [103], αSyn in human-derived iPSC brain organoids assembles into large Lewy body (LB)-like aggregates when exposed to pre-formed fibrils (PFFs) [104], and midbrain organoids derived from individuals carrying GBA mutations produce fibrillary aggregates with seeding activity capable of propagating pathology when exposed to healthy control organoids [105]. Experiments with iPSCs can help determine how specific disease-associated mutations can impact the spread of αSyn aggregation [102, 105]. Additionally, the use of organoids composed of multiple different cell-types acting as a biological unit with more natural, functional, and biologically relevant synaptic-like connections can help clarify αSyn pathology propagation through neural circuits [102, 105]. Inoculation and primary uptake Cell culture-based studies focus primarily on inoculation, primary uptake, and primary release (Fig. 2A-B). The inoculum is added to the media and includes various forms of αSyn: protein fragments, full length monomers, oligomers of various sizes in beta-sheet and alpha-helical conformations, or PFFs. The precise conformation and structure of αSyn-aggregate-containing inoculum is not always clearly defined, but presumably includes some higher-order configuration that we describe as “oligomers”, unless otherwise noted. Inoculum can also be homogenates of human brain specimens, or components of human cerebrospinal fluid (CSF) that have been concentrated or amplified to induce fibrilization.Fig. 2Insights from the study of αSyn aggregate propagation in cell culture systems. (A) Mechanisms of primary uptake supported by cellular models include receptor-mediated endocytosis by several candidate receptors, including Lag3 (depicted by teal transmembrane protein), membrane translocation, and macropinocytosis. Extracellular vesicles may transmit αSyn aggregates via fusion with the cell membrane or endocytosis. There is conflicting evidence as to whether primary uptake occurs at dendritic, somatic, or presynaptic compartments. (B) Supported mechanisms of primary release include extracellular vesicle production, exocytosis (such as SNARE-mediated processes depicted by yellow, red, and green peri-vesicular proteins), tunneling nanotubes, and gap junctions (red hexamer). Of note, αSyn oligomers have only been observed in tunneling nanotubes within lysosomes and vesicles but are depicted as cytosolic for clarity. Similarly, αSyn aggregates are too large to fit through a gap junction pore, but the true mechanism of uptake via connexins is unknown. (C) Cellular models have implicated receptor-mediated endocytosis in secondary uptake (possibly mediated by the Lag3 protein depicted in teal) Insights from the study of αSyn aggregate propagation in cell culture systems. (A) Mechanisms of primary uptake supported by cellular models include receptor-mediated endocytosis by several candidate receptors, including Lag3 (depicted by teal transmembrane protein), membrane translocation, and macropinocytosis. Extracellular vesicles may transmit αSyn aggregates via fusion with the cell membrane or endocytosis. There is conflicting evidence as to whether primary uptake occurs at dendritic, somatic, or presynaptic compartments. (B) Supported mechanisms of primary release include extracellular vesicle production, exocytosis (such as SNARE-mediated processes depicted by yellow, red, and green peri-vesicular proteins), tunneling nanotubes, and gap junctions (red hexamer). Of note, αSyn oligomers have only been observed in tunneling nanotubes within lysosomes and vesicles but are depicted as cytosolic for clarity. Similarly, αSyn aggregates are too large to fit through a gap junction pore, but the true mechanism of uptake via connexins is unknown. (C) Cellular models have implicated receptor-mediated endocytosis in secondary uptake (possibly mediated by the Lag3 protein depicted in teal) Significant evidence posits that different conformations of αSyn are taken up by classical receptor-mediated endocytosis (RME) involving dynamin (PFFs in SH-SY5Y, COS-7, and CAD cells), clathrin (PFFs in cultured microglia), Rab35 and associated calcium signaling pathways (PFFs in STC-1 and SH-SY5Y cells), and Rab5A (monomers in rat primary culture neurons) [84, 104, 106–108]. Endocytosis of small soluble αSyn aggregates and PFFs has also been demonstrated in mouse and rat primary neuron culture, astrocytes derived from human embryonic stem cells (hESC), HEK-293 cells, SKMel5 cells, PC12 cells, and Neuro-2a cells [80, 93] (Fig. 2A). Several molecules have been identified as potential mediators of αSyn uptake. Heparan sulfate proteoglycans (HSPGs) have been shown to facilitate αSyn PFF endocytosis in HEK293 cells, Neuro-2a cells, and mouse primary culture [82, 109, 110]. HSPGs are hypothesized to regulate endocytosis of αSyn PFFs by enhancing the electrostatic interactions between PFFs and the membrane, and to induce clathrin-mediated endocytosis via recruitment of myosin-7B and actin [110]. β-Neurexins have also been found to bind αSyn fibrils and neurexin-1β mediates the specific uptake of acetylated αSyn fibrils [111, 112]. Alternatively, lymphocyte-activation gene 3 (Lag3) has been proposed as a specific receptor mediating αSyn PFF endocytosis in SH-SY5Y, HeLa, COS7, HEK-293 cells, as well as mouse primary cortical neurons [94] (Fig. 2A). Uptake by Lag3 may be facilitated by amyloid precursor-like protein 1 (APLP1) [113]. Endocytosis of monomeric and small soluble oligomeric beta-sheet containing αSyn aggregates arranged in globular and cylindrical structures was also shown to be mediated by the low-density lipoprotein receptor-related protein 1 (LRP1) in iPSC-derived neurons [114]. In addition, the PD risk gene FAM171A2 promotes αSyn fibril endocytosis in Neuro-2a cells, HEK293 cells, and mouse primary cortical neurons [115]. However, RME is not the only proposed mechanism of αSyn aggregate entry, and a recent study in Neuro-2a cells showed that inhibition of several different endocytosis pathways did not diminish PFF internalization, casting doubt on its role as the main driver of αSyn seed uptake [116]. Extracellular vesicles (EVs; also called exosomes) are a proposed alternative mechanism of transmission of seed-competent αSyn aggregates (Fig. 2A). In vitro experiments utilizing fluorescently labeled exosomes demonstrate that EVs protect αSyn from extracellular degradation and are internalized by recipient cells at a significantly higher rate than non-membrane-enveloped, monomeric αSyn [90]. Exposure to exosomes isolated from human PD CSF induces αSyn aggregation in culture biosensor cells, recruiting the cell’s native soluble αSyn into dense inclusions [117]. Uptake of EVs is proposed to occur via distinct, less well-characterized pathways [81, 118]. Delivery of EV cargo to the recipient cell can happen through two primary mechanisms: direct membrane fusion of EVs with the plasma membrane and delivery of cargo directly into the cytoplasm [119, 120] or endocytosis of the entire EV into a multivesicular endosome [118, 121]. For the αSyn seed to reach the cytosol from the multivesicular endosome, the EV membrane may back-fuse with the endosomal membrane [122, 123]. Alternatively, the vesicle may be degraded within the endosome, releasing its contents into the lumen and the endosome may then rupture to release the seeds into the cytosol [124–127]. Monomers and fragments of αSyn can enter cells via membrane translocation (Fig. 2A), but this phenomenon has only been observed in cellulo and requires supra-physiological concentrations of αSyn [128]. A short 11 amino acid sequence in the N-terminal region is capable of facilitating diffusion of αSyn across the cell membrane of CHO-K1 and Leukemia K562 cells and inhibition of endocytosis and other energy-dependent pathways did not impair uptake [128]. However, studies have repeatedly demonstrated that exposure to monomers does not trigger aggregation of endogenous αSyn in immortalized cell lines (HEK293, SH-SY5Y, or COS-7 cells), primary cultures, or stem-cell-derived glia [80, 106, 129, 130]. Similarly, in vitro analyses of aggregation kinetics have shown that exceedingly high concentrations of monomers are required to induce aggregation [131]. In contrast, exposure to mutated monomers, such as the A53T variant, or WT monomers in the setting of proteostatic stress has been shown to trigger spontaneous primary nucleation and endogenous αSyn aggregation [25, 132, 133]. In addition, fragments of αSyn, specifically truncated forms including only the first 95 amino acids, do appear capable of corrupting endogenous αSyn and triggering aggregation [25]. The relevance of inter-cell transmission of single peptides to the propagation of αSyn-related pathologies therefore remains unclear and further in cellulo and in vivo work is required. Another alternative uptake pathway involves macropinocytosis of αSyn PFFs through interactions with networks of actin filaments [116, 124] (Fig. 2A). This process may also involve HSPGs and/or the Ca2+-calmodulin-calcineurin signaling pathway [109, 134]. The broad range of proposed uptake mechanisms may be a byproduct of diverse experimental approaches or a reflection of αSyn’s true dynamic ability to enter cells via multiple distinct pathways. The most pathophysiologically significant mechanism underlying primary uptake remains controversial, with several candidates being proposed but little consensus (Fig. 2A). Primary release Primary release has been assessed with cells pre-incubated with αSyn oligomers or fibrils, cells transfected or transduced to overexpress different forms of αSyn, or cells cultured from transgenic animals. Several studies suggest exocytosis as the main route of egress for αSyn aggregates [15, 135–139] (Fig. 2B). Several molecules linked to non-classical exocytosis pathways have been implicated, including Tubulin Polymerization-promoting Protein (TPPP/p25), USP19, and VPS4. Calcium-regulated, SNARE-dependent exocytosis of lysosomal contents has also been shown to facilitate αSyn oligomer release [140]. It is theorized that in the setting of stress, potentially toxic protein aggregates, including αSyn, are exocytosed in a compensatory effort to maintain homeostasis. Alternatively, EVs have been suggested as a means of primary release [63, 90, 141–143] to similarly combat cellular stress (Fig. 2B). Secretion of small EVs is hypothesized to increase when the autophagic-lysosomal degradation system is compromised [63, 64] and toxic intracellular αSyn aggregates are redirected toward multivesicular bodies for extracellular export rather than degradation [65]. The transmembrane protein TMEM16F appears capable of modulating the release of seeding-competent αSyn aggregates from cultured mouse neurons either through EVs or membrane translocation [144], but the precise mechanism has not been clearly defined. Tunneling nanotubes (TNT) [84, 129] and gap junctions [145, 146] have been proposed as mechanisms of transmission that encompass both primary release and secondary uptake (Fig. 2B). αSyn fibrils inside of lysosomes have been observed within TNTs connecting neurons in primary culture [84]. Compromising the integrity of these lysosomes accelerates the spread of αSyn aggregation between neurons and CAD cells and between CAD cells and HeLa cells [85]. Conversely, preventing cell-to-cell contacts reduced the spread of αSyn aggregation between neurons and between neurons and CAD cells [84, 85]. Other studies have found that TNTs mediate αSyn aggregate transmission between SH-SY5Y cells and primary human brain pericytes [147], between human astrocytes [129], between microglia [148], and bidirectional transfer between neurons and microglia in co-cultures [149]. The gap junction protein connexin has also been found to mediate the uptake and inter-cell transfer of αSyn oligomeric assemblies (Fig. 2B) in SH-SY5Y cells, primary rat neurons, and OLN-93 cells [145, 146]. It remains unclear how αSyn aggregates could fit through the small connexin pore and why this process appears to require energy expenditure. Rather than acting as a true channel, connexins may instead facilitate uptake via co-endocytosis of the hemichannel-oligomer complex [145], but this remains speculative. Secondary transmission steps Less attention has been paid to secondary steps of αSyn pathology propagation. A small number of studies have used microfluidic devices to separate populations of cells to interrogate secondary uptake. These experiments have reinforced the role of RME involving Lag3 [94] (Fig. 2C). In addition, studies in SH-SY5Y and primary rodent neuron culture in microfluidic devices have suggested a function for 14-3-3 protein as a regulator of secondary uptake of αSyn oligomers whose presence reduces aggregation propagation [150]. Interestingly, 14-3-3 is also an established CSF biomarker for rapid neurodegeneration in classic prion disorders like Creutzfeldt-Jakob disease, suggesting a corresponding molecular chaperone response to different aggregating proteins [151]. One limitation of experiments exploring secondary uptake and subsequent steps in the propagation pathway is that the inoculum is not always clearly labeled and therefore not readily differentiated from the release of primary seeds. This leaves open the possibility that the inoculum itself is transferred to neighboring cells rather than corrupted endogenous αSyn. Indeed, this has been shown to occur in multiple cell culture systems, including primary cortical mouse neurons and human iPSCs [24, 152, 153]. Other insights from in cellulo models Across the different steps in pathological propagation and regardless of the specific pathway implicated, cellular stress, such as impairments of lysosomal or mitochondrial function or disruption of autophagy or proteasomal pathways, appears to increase the release of αSyn [64, 66, 67]. Importantly, leaking of αSyn through compromised cell membranes does not appear to be a significant contributor to pathological propagation [154]. Together, these data argue that pathologic αSyn seeds are released by cells in an effort to maintain homeostasis in the face of external or internal insults. Cellular models have also been used to assess the trafficking of αSyn aggregates after internalization, demonstrating both anterograde and retrograde movement of αSyn in various oligomeric configurations across cultured cells [24, 93, 152, 153, 155, 156]. In addition, studies in Neuro-2a cells suggest that αSyn aggregates interact directly with microtubules to be actively transported between subcellular compartments [157]. Posttranslational modifications (PTMs) are critical in protein sorting and trafficking and are therefore likely important to the excretion of seeding-competent αSyn amyloid oligomers from affected cells. Several recent studies have attempted to address this question indirectly, suggesting oxidative modifications, glycosylation, or C-terminal truncation promote primary release in cultured cells [158, 159]. In addition, there is limited evidence that non-acetylated αSyn PFFs may have diminished uptake [111]. These studies argue that differences in cellular properties lead to different PTMs and contribute to selective vulnerability to uptake or propensity for excretion across cell-types. However, the relevance of phosphorylation, glycosylation, ubiquitination, acetylation and truncations on the propagation of αSyn pathology remains unclear. This is, in part, due to the difficulty in disambiguating the effects of PTMs on aggregation and toxicity in general from its specific importance in transcellular release and uptake. Although challenging, this question deserves further study, as altering the intracellular trafficking of αSyn aggregates may represent an effective means of retarding pathological spread. Functional synapses or even primitive cell-to-cell contacts are not necessary for αSyn aggregate uptake and release in cultured cells [24, 84, 155]. However, recent studies highlight that increasing neuronal activity or increasing synaptic vesicle exocytosis increases the release of non-fibrillar, soluble αSyn oligomers and monomers in cultured cells [56] and human iPSC-derived dopaminergic neurons [55], respectively. The precise location of αSyn aggregate release and uptake remains unclear and the lack of true synaptic connections in most cell culture systems limits the ability of in cellulo approaches to adequately address this question. However, organoids with more natural synaptic-like connections [102, 105] may be of use in future studies seeking to determine if transfer occurs at the synapse, at extra-synaptic neuronal contacts, or across the extracellular matrix of simply adjacent cellular structures. A particular strength of cellular systems is the use of fluorescent labels to track αSyn’s transit into, through, and out of cells. These techniques have helped identify putative pathways that facilitate transmission, such as RME [94, 115] and TNT [84]. Similarly, the ability to differentially label αSyn from different sources has confirmed the ability of inoculum to corrupt endogenous αSyn [86, 93, 160]. However, these studies generally focus on the transit and seeding properties of the inoculum rather than primary or secondary aggregates and must therefore be interpreted with caution. Indeed, PFFs can be disassembled into amyloid oligomeric and monomeric species by molecular chaperones, making it difficult to distinguish what is exogenously introduced versus endogenously templated [161]. An additional caveat of labeled αSyn includes potential interference with its physiological and pathological activities. GFP and mCherry tags have been shown to alter αSyn aggregate morphology [162], αSyn phase separation [163], and seeding kinetics [164]. Even small organic tags can alter aggregation kinetics, often shortening fibril length and altering fibril morphology [165, 166]. In conjunction with biochemical assays, cell culture systems have demonstrated that αSyn aggregates generated under different in vitro conditions or obtained from patients with different synucleinopathies have different transmission and seeding properties and induce the formation of aggregates with similar properties compared to the inoculum [83, 138, 167–172]. These data support the theory that the structural and biochemical composition of the αSyn aggregates themselves dictate pathology and disease severity and progression. However, differences in the mechanism of uptake and release of different αSyn aggregate strains have not been directly interrogated using in cellulo methods. Strengths and limitations of in cellulo approaches With their unparalleled control over experimental conditions, cell culture models have the potential to produce deep mechanistic understanding into the propagation of αSyn aggregation. However, as detailed above, in cellulo approaches have yielded disparate and often conflicting results. Correspondingly, cell culture systems have highlighted the ability of many different proteins acting in a variety of different pathways to either promote or inhibit transmission, with one screen in HEK293 cells discovering 38 genes impacting αSyn monomer transmission, including SLC30A3, ADAMTS19, POLR2A, POLR2B, and WEE1, and involving diverse cellular processes such as signaling pathways, cytoskeletal structure, waste disposal, cell death, oxidative stress responses, and DNA repair [173]. Additionally, all the proposed mechanisms of transfer and their associated proteins are ubiquitous and do not provide insight into subcellular localization or cell-type susceptibility. Indeed, both the axonal/presynaptic and somatic/dendritic compartments of neuronal cells in culture can take up αSyn seeds [24, 93, 156] (Fig. 2A). The variety of cell types that can be inoculated by αSyn seeds suggests a pervasively expressed pathway or multiple means of entry. Importantly, immortalized cell lines, like HEK293 cells, do not possess the complex architecture of neurons with presynaptic, dendritic, and somatic compartments that may play distinct and pivotal roles in αSyn pathological aggregation and transmission [174]. Although primary neuron cultures and iPSC-derived neuron cultures do possess clear presynaptic boutons with concentrated αSyn, they do not fully recapitulate physiological, bona fide, in vivo synapses functioning as part of coherent neural circuits [175–177], features that may be critical determinants of αSyn pathological propagation. These factors, in conjunction with the variety of cell-types used and inoculation paradigms applied, may explain these wide-ranging findings. Overall, data from cellular studies are a testament to αSyn’s robust ability to transfer into and out of cells through diverse pathways (Fig. 2). These approaches have clearly demonstrated that when fibrillar αSyn is exogenously applied to cells, it corrupts native αSyn to similarly misfold and aggregate. They have firmly established αSyn’s prion-like properties and have, as such, significantly advanced the field and enhanced our understanding of synucleinopathy pathogenesis. They remain important tools for examining the molecular and biophysical mechanism(s) of αSyn aggregation. Regarding the propagation of αSyn pathology across cells, they have identified potential receptors for uptake and proteins mediating release, but the relevance of these results to the actual pathogenesis and pathophysiology of synucleinopathies needs to be tested more systematically in vivo. The variable conclusions drawn from cellular studies highlight their main limitation: they cannot recapitulate the in vivo neuronal architecture, intricate circuit structures, complex extracellular milieu, and diverse neuroanatomic locations in which the actual disease occurs. While they have established a broad landscape of what can facilitate αSyn aggregate transmission, they are unable to isolate clinically relevant mechanisms. As such, they are not effective screening tools at this stage in our understanding. In the future, these approaches will be most effective if used to further explore the mechanism of established routes of transmission or to screen modulators of proteins and pathways that have a definite role in pathological propagation. When used in the appropriate context, the advantages afforded by cellular models will provide significant mechanistic insight. Invertebrate models Invertebrates do not express αSyn, presenting a particular challenge to studying inter-cell transmission of pathology. Transgenic Caenorhabditis elegans and Drosophila melanogaster have been generated to model synucleinopathies and have provided important insights into the contributors of αSyn aggregation and the resultant cellular dysfunction [178–188]. There is evidence that αSyn can be transmitted between Drosophila neurons [189], but there are no established fly models focused on propagation. C. elegans, however, have been used to study trans-cellular propagation of αSyn aggregation. Labeling αSyn with different fluorescent markers in different cells has revealed synaptic transfer of αSyn via exocytosis and endocytosis leading to oligomerization [190]. In addition, exposing transgenic αSyn expressing C. elegans to PFFs induces HSPG-dependent αSyn aggregation in neurons within the worm head, including subsets of dopaminergic neurons [191] (Fig. 3).Fig. 3Insights from Caenorhabditis elegans models used to study αSyn aggregation propagation. (A) Transgenic worms expressing human αSyn fed with PFFs (blue) develop aggregation of host αSyn in sensory head neurons (brown ellipsoids), including a subset of dopaminergic neurons, adjacent to the pharyngeal bulb (light brown area). Orange circles indicate neurons experiencing αSyn aggregation. Arrows indicate neuron-to-neuron propagation of αSyn pathological aggregation. (B) Studies in Caenorhabditis elegans suggest heparan sulfate proteoglycan (yellow protein with green glycosylation chains) mediated endocytosis as the mechanism of uptake of αSyn aggregates Insights from Caenorhabditis elegans models used to study αSyn aggregation propagation. (A) Transgenic worms expressing human αSyn fed with PFFs (blue) develop aggregation of host αSyn in sensory head neurons (brown ellipsoids), including a subset of dopaminergic neurons, adjacent to the pharyngeal bulb (light brown area). Orange circles indicate neurons experiencing αSyn aggregation. Arrows indicate neuron-to-neuron propagation of αSyn pathological aggregation. (B) Studies in Caenorhabditis elegans suggest heparan sulfate proteoglycan (yellow protein with green glycosylation chains) mediated endocytosis as the mechanism of uptake of αSyn aggregates Invertebrate models combine the natural, in vivo settings with powerful genetic tools to study the mechanisms of αSyn aggregation propagation. In addition, they can provide readouts on animal behavior. However, the lack of endogenous αSyn and the protein’s established robust ability to transfer between cells, as demonstrated in cellular models, introduces significant caveats regarding physiological relevance. Like in cellulo models, they will be most effective when they are used to address specific questions regarding established pathways. Rodent models Rodent models have been indispensable for understanding synucleinopathies and unraveling mechanisms of how αSyn dysfunction underlies disease pathology and progression. They capture the anatomical connectivity and physiological interdependence of the mammalian nervous system, an essential feature lacking in in cellulo systems [192, 193]. They allow for direct interrogation of propagation through defined circuits, such as vagal, nigrostriatal, olfactory, limbic, and intra-cortical pathways as well as connections linking peripheral and central structures [14, 49, 74, 157, 194–199]. They also permit assessment of electrophysiological changes, motor deficits, and other behavioral phenotypes [200–202]. This level of analysis is a significant advantage in clarifying how molecular pathology maps onto system-level dysfunction. The established suite of powerful genetic tools available in rodents and the evolutionary conservation between mice and humans also enables targeted molecular manipulations with translational implications [203, 204]. Rodent models therefore provide important context for the multiple factors that may work in concert to spread αSyn pathology, including genetic background, neuroanatomy and connectivity, and cell type-specific vulnerability. Inoculum Inoculation in rodent models involves injection of purified αSyn assemblies (oligomers or PFFs), components of human tissue, or viruses driving expression of αSyn into target tissues [192, 205]. Each approach introduces distinct strengths and interpretive caveats. PFF-based inoculations have become the most widely used paradigm, providing a reproducible and spatially confined seed for initiating pathology. Injection into specific loci, such as the striatum, olfactory bulb, or gut wall, produces temporally defined propagation to connected neuropils [206]. PFFs derived from mouse and human αSyn have both been used, with mouse αSyn PFFs generally showing greater pathogenicity when used at the same concentration [198, 207]. This may be driven by similarity between PFFs and host (mouse) αSyn, but it has not been definitively determined (see also below). In contrast, transduction by viral vectors allows region- and cell-type-specific overexpression of αSyn that induces aggregation and subsequent propagation to non-transduced cells [62, 158, 197, 208, 209]. This approach avoids the introduction of large amounts of non-physiological and exogenous extracellular αSyn [210] that are not part of true synucleinopathy pathogenesis. Although it has the advantage of triggering pathology intracellularly, it nonetheless rapidly induces high expression of normal or aggregate-prone isoforms of αSyn to supraphysiologic levels that are also inconsistent with actual disease [210]. It also may introduce local inflammatory responses [211, 212]. It is unclear if the associated inflammation is a confounding feature of this approach that limits interpretability, or if it is an advantage that recapitulates the inflammatory response observed across synucleinopathies [213–217]. Both PFF and viral transduction bypass the inciting events that trigger αSyn aggregation in actual disease. The former creates foci of nucleation to recruit endogenous αSyn and the latter overcomes the thermodynamically unfavorable process of primary nucleation of monomers through overexpression and modifications (truncations, mutations). Although viral transduction requires an additional lag time for oligomers to assemble, both approaches significantly accelerate the aggregation process compared to actual disease and require supra-physiologic concentrations of αSyn [218, 219]. However, both PFF- and virus-based approaches have demonstrated that the anatomical site of initiation strongly determines the subsequent pattern of spread and phenotypic outcome [41, 74, 196, 198–200, 208, 210, 220]. Thus, while they provide limited insight into the initiating events of sporadic synucleinopathies, they can model propagation and form the foundation for probing downstream mechanisms of intercell transmission and selective neuronal vulnerability. Inoculation, primary uptake, primary release Non-fibrillar and fibrillar αSyn species are internalized within minutes to hours after olfactory bulb or striatal administration [41, 207, 220]; furthermore, exogenous LB-enriched fractions from post-mortem brains of PD patients are rapidly taken up by host neurons when injected into the nigrostriatal axis [27]. Mechanistically, there is evidence that internalization proceeds through RME, though the precise mediators remain incompletely defined [15, 41, 109] (Fig. 4A). Candidate neuronally-expressed receptors such as FAM171A2, APP-like proteins, and HSPGs have been implicated in studies using mouse models inoculated with αSyn PFFs, consistent with findings from in cellulo and invertebrate models [109, 113, 221]. Lag3 has also been suggested to facilitate uptake of αSyn aggregates through RME, but its expression in neurons and specific role are controversial [94, 113]. LAG3 knockout mice injected with αSyn PFFs in the dorsal striatum showed reduced αSyn aggregation, dopamine loss, and motor impairments compared to WT mice, suggesting that Lag3 may be crucial for αSyn PFF uptake and resultant neurodegeneration [94]. However, subsequent studies were unable to replicate these findings nor detect neuronal expression of Lag3 [222].Fig. 4Insights from the study of αSyn aggregate propagation in rodent models. (A) Studies implicate receptor-mediated endocytosis by several candidate receptors, including Lag3 (depicted by teal transmembrane protein) at axon terminals (black dashed box) as the mechanism of primary uptake with subsequent retrograde transport to somatic and dendritic compartments (black arrow). (B) Rodent models suggest primary release (upper panel) is mediated by exocytosis (possibly with SNARE-mediated vesicle fusion depicted by yellow, red, and green peri-vesicular proteins), and secondary uptake (lower panel) is achieved through receptor-mediated endocytosis (possibly via Lag3, depicted by teal transmembrane protein). (C) Inoculation (indicated by asterisk and/or syringe) in different locations in the rodent body and brain demonstrate both caudal-to-rostral (red) and rostral-to-caudal (blue) propagation of αSyn aggregation with patterns of spread highly dependent on the site of inoculation with evidence for both retrograde and anterograde propagation (AON, anterior olfactory nucleus; C/P, caudate/putamen; H, hippocampus; HyT, hypothalamus; M, Medulla; Mb, midbrain; OB, olfactory bulb; P, Pons; S, ventral striatum; T, Thalamus) Insights from the study of αSyn aggregate propagation in rodent models. (A) Studies implicate receptor-mediated endocytosis by several candidate receptors, including Lag3 (depicted by teal transmembrane protein) at axon terminals (black dashed box) as the mechanism of primary uptake with subsequent retrograde transport to somatic and dendritic compartments (black arrow). (B) Rodent models suggest primary release (upper panel) is mediated by exocytosis (possibly with SNARE-mediated vesicle fusion depicted by yellow, red, and green peri-vesicular proteins), and secondary uptake (lower panel) is achieved through receptor-mediated endocytosis (possibly via Lag3, depicted by teal transmembrane protein). (C) Inoculation (indicated by asterisk and/or syringe) in different locations in the rodent body and brain demonstrate both caudal-to-rostral (red) and rostral-to-caudal (blue) propagation of αSyn aggregation with patterns of spread highly dependent on the site of inoculation with evidence for both retrograde and anterograde propagation (AON, anterior olfactory nucleus; C/P, caudate/putamen; H, hippocampus; HyT, hypothalamus; M, Medulla; Mb, midbrain; OB, olfactory bulb; P, Pons; S, ventral striatum; T, Thalamus) There is only limited evidence for EV-mediated primary uptake, with striatal injection of exosomes associated with small prefibrillar αSyn oligomers taken from PD patient serum causing local protein aggregation (αSyn, ubiquitin, P62), dopaminergic degeneration, and microglial activation in mice [223]. Conversely, intrastriatal injection of αSyn-laden exosomes failed to trigger endogenous αSyn accumulation in WT mice [224]. Inoculation experiments in rodents have also revealed that different neuronal subtypes are more or less efficient at taking up αSyn seeds, with cholinergic neurons appearing especially vulnerable [34]. The unique features or molecular pathways of this population that mediate this enhanced uptake are unknown. Less is known about primary release, and most of the available evidence is indirect. A recent study in the mouse has highlighted the importance of activity-dependent, SNARE-mediated lysosomal exocytosis as a key pathway for the release of pathologic αSyn aggregates across all steps in the propagation process. In conjunction with cell culture experiments, this study found αSyn aggregates accumulating in neuronal lysosomes and released via VAMP7/SNAP23, Ca2+-dependent exocytosis producing non-membrane-enveloped, seeding-competent extracellular aggregates [140] (Fig. 4B). Inhibition of the Ca2+-calmodulin-calcineurin signaling cascade has been shown to slow αSyn uptake by macropinocytosis and subsequent propagation of aggregation after inoculation with PFFs in the mouse olfactory bulb, suggesting a role for Ca2+-dependent signaling across multiple phases of transmission as well [134]. Secondary transmission steps The mechanisms underlying secondary uptake are less well studied, with mostly circumstantial evidence implicating endocytic pathways (Fig. 4B). Studies implanting healthy neurons into diseased brains or diseased neurons into healthy brains demonstrate host-to-graft and graft-to-host transmission with endocytosis-like uptake by recipient neurons [15]. Lag3, which has been proposed to play a role in primary uptake in vitro and in rodent models, may also play a role in secondary uptake and the further spread of endogenous αSyn aggregation: LAG3 conditional knockout mice injected with αSyn PFFs in the dorsal striatum showed significantly less αSyn pathology in secondary brain regions including the cerebral cortex, striatum, amygdala, substantia nigra, and entorhinal cortex compared to control mice [225]. While this posits a potential role for Lag3 in secondary uptake and further propagation, conflicting findings about Lag3’s neuronal expression and its more established role in primary uptake of PFFs are a significant complication that limits interpretation [222]. Evidence for other mechanisms of secondary uptake in rodents is more limited. αSyn aggregates have been observed to transfer between engrafted neurons and microglia through TNT-like contacts in the mouse brain [148], but the significance of these findings remains unclear. Across all stages of propagation, the genetic background and cellular context (lysosomal deficits or oxidative stress) can amplify the degree of αSyn pathology spread, mirroring observations from cell culture experiments [21, 62, 194, 195]. αSyn aggregate structure impacts propagation As in cell culture experiments, the specific conformation of the αSyn aggregates can significantly impact the rate and extent of pathology. The strain hypothesis proposes that conformationally distinct assemblies of misfolded αSyn self-propagate their unique architecture during templated recruitment of endogenous αSyn [226, 227]. Strain identity dictates higher-order structural features, conferring stable and transmissible differences in seeding potency, neuroanatomical spread, and toxicity [228]. Distinct strains of αSyn oligomers and fibrils are thought to contribute to the pathological heterogeneity of synucleinopathies. Rodent studies have employed several classes of αSyn assemblies, each with important biological differences. Mouse αSyn PFFs are generated from the murine sequence and efficiently seed endogenous mouse αSyn, providing robust and reproducible spread of pathology [14, 229, 230]. However, they are formed under in vitro conditions that may not capture the conformational landscape of patient-derived aggregates shaped by cellular factors and post-translational modifications. Structural studies using solid state nuclear magnetic resonance (SSNMR) to compare mouse and human αSyn fibrils have demonstrated that the species share remarkably similar secondary structure and protofilament 3D structure [231]. However, subsequent studies comparing human and mouse αSyn fibril structures showed that mouse αSyn fibrils display altered packing arrangements, reduced hydrophobicity, and exacerbated pathological spread in neurons and humanized αSyn mice, highlighting potential limitations of mouse αSyn fibrils in modeling propagation of human αSyn fibrils in pathological contexts [232]. A complementary approach is to use recombinant human αSyn PFFs in rodents expressing either native or human αSyn to explore species-specific templating properties of both the inoculum and the endogenous, corrupted protein [206]. Patient-derived or patient-amplified αSyn fibrils are also commonly used as inoculum in rodent experiments. Studies using SSNMR or cryo-electron microscopy demonstrate that such fibrils retain disease-associated structural features, such as variations in protofilament organization, which facilitate fibrilization or aggregation, and often display distinct cell-type tropism and regional vulnerability in vivo [27, 28, 172, 233–235]. Mutations and PTMs have also been shown to contribute to unique αSyn fibril conformations [233]. These structural differences are associated with strain-dependent variation in regional vulnerability, time to disease onset, and conformational properties of induced aggregates [228]. Thus, while mouse and recombinant human PFFs offer experimental control and reproducibility, patient-derived or mutant fibrils may better capture strain-specific features of human synucleinopathies, albeit with greater heterogeneity and technical variability. αSyn aggregate structure can also be influenced by cell type: oligodendrocytes can generate glial cytoplasmic inclusions (GCIs) in MSA that have distinct structures and phosphorylation patterns and have significantly greater seeding potency than neuronal αSyn inclusions [236]. It is uncertain how seed structure impacts trans-cellular propagation, but there have been studies showing that secondary spread is shaped by strain properties. For example, oligodendrocyte-derived GCI-like αSyn aggregates showed increased spread into the entorhinal cortex, hippocampus, and piriform cortex and less efficient spread into neocortical regions such as motor cortex when compared to mouse PFFs or neuronally-derived αSyn aggregates [236]. This demonstrates that αSyn structure influences the neuroanatomical spread patterns, but further mechanistic details of how this happens are not clear. Importantly, how αSyn seed structure impacts uptake and release has not been directly assessed nor disentangled from their differing ability to induce endogenous αSyn aggregation. It is therefore unclear if different αSyn strains have different means of entry and exit from cells and the relationship between trans-cellular transmission and propensity to induce local aggregation. Further work is needed to fully understand the distinct drivers of both propagation and aggregation in human disease. Circuit-based propagation Beyond the specific mechanism of uptake and release, rodent models can also provide systems level insight into the trans-cellular spread of αSyn aggregation. Rodent models have consistently demonstrated network-based propagation of αSyn pathology across anatomically connected brain regions, whereby templated misfolding spreads along established neuronal pathways, producing regionally and temporally defined patterns of inclusion formation (Fig. 4C). The relative importance of the direction of propagation, anterograde or retrograde, to pathological transmission remains controversial. The preponderance of evidence supports retrograde spread. Striatal or midbrain inoculations lead to retrograde spread within the nigrostriatal system, culminating in selective DA neuron loss and motor deficits [14, 49, 74, 194, 196, 220]. Retrograde propagation within the CNS has been observed in rodent models following injection of adeno-associated viruses (AAVs) to overexpress human αSyn in the vagus nerve, resulting in caudo-rostral spread of exogenous protein from the medulla through the pons, midbrain, and forebrain [197]. Retrograde spread of pathology from peripheral areas into the CNS has also been demonstrated. Injection of PFFs into hind limb muscles of rodents overexpressing αSyn results in progressive, retrograde, trans-synaptic spread of Lewy pathology through the spinal cord and up to motor cortex [194]. Similarly, inoculations by PFFs or human post-mortem extracts demonstrate retrograde transmission along the vagus nerve, from both the enteric nervous system and the kidney, to the dorsal motor nucleus and midbrain, consistent with the gut-brain axis hypothesis and Braak’s staging framework [36, 157, 195, 198, 199, 237–239]. Some studies have found that peripheral-to-central propagation is limited without background overexpression of αSyn [240, 241]. However, robust retrograde spread into the CNS has been observed even in WT animals. For example, peripheral injection of PFFs into WT mice or rats induced widespread aggregation in vagal nuclei that then progressed into pontine, midbrain, and cortical areas [198, 242]. Similarly, AAV-mediated overexpression of human αSyn in the rat vagus nerve led to significant rostral propagation of the pathology [197]. Furthermore, overexpression of αSyn in enteric neurons led to spread of αSyn aggregation into the CNS [243]. Vagotomy appears to prevent spread of pathology from gut to brain suggesting a critical contribution of vagal pathways to retrograde peripheral-to-central propagation [198, 237, 243]. Furthermore, network modeling has revealed that the retrograde connectivity is among the best predictors of the pattern of αSyn propagation [33]. In support of retrograde transmission, aggregation following inoculation often begins in pre-synaptic and axonal compartments before spreading to the soma. This has been consistently shown in rodent models across inocula and anatomical regions, including PFFs injected into the motor cortex [194], αSyn aggregate extracts derived from PD patients injected into striatum [27], viral overexpression of A53T αSyn in the striatum [244], and transduction of human αSyn by AAVs into the vagus nerve [197]. Across these experimental paradigms, aggregates first appear in axons producing pathology, such as axonal varicosities, before propagating towards somatic and finally dendritic structures [197, 208]. The extensive axonal arborization and large number of synaptic terminals [245] packed with αSyn may make dopaminergic neurons of the substantia nigra especially vulnerable to pathology [34]. One group injected PFFs into the pedunculopontine nucleus (PPN) of the brainstem in WT mice and mapped the pattern of αSyn spread compared to brain-wide connectomes determined by monosynaptic rabies virus mapping, finding that most neurons in the brain making synaptic contact with the PPN showed signs of αSyn pathology and that spread occurred in a retrograde direction to innervating structures [34]. However, there was no consistent relationship between the number of synaptic connections in a region and the number of cells showing αSyn pathology. This suggests that while anatomic connectivity constrains the spread of αSyn pathology, other factors such as cell type, play a critical role in determining the pattern and extent of spread. Such in vivo findings add to the uncertainty surrounding findings from in cellulo models regarding the necessity of functional synaptic connections for pathological propagation [24, 84, 155]. Further work must be done to determine the extent to which synaptic connectivity impacts propagation. Despite this body of work, there is also significant evidence for anterograde spread. Striatal injections of Lewy body-derived extracts from PD patients and PFFs in mice caused accumulation of αSyn and inclusion formation in nigral neurons and interconnected regions in both anterograde and retrograde directions [27, 246]. Injection of fibrils into the substantia nigra results in anterograde spread into the dorsal striatum as well as the amygdala, piriform cortex, and thalamus [247]. Olfactory bulb injections of PFFs drive rostro-caudal anterograde dissemination through limbic and cortical networks (substantia nigra, locus coeruleus, raphe nuclei) [41, 207]. Rostro-caudal anterograde spread is also observed after PFF injection into the prefrontal cortex towards subcortical, midbrain, and brainstem structures [248]. Stimulating neuronal activity with picrotoxin in freely moving mice led to an increase in extracellular αSyn, possibly via synaptic vesicle exocytosis [56] and thereby arguing for anterograde transmission. Pathology in the brain can spread caudally to peripheral tissues in an anterograde direction in rats following human αSyn overexpression by AAVs [249]. Collectively, studies of spread in rodent models underscore that αSyn can propagate in both retrograde and anterograde directions, but the relative dominance of each route in actual disease remains unresolved and may depend on the initiating site, neuronal subtype, and circuit architecture. Defining the conditions favoring anterograde versus retrograde spread and how this shapes disease progression remains a critical knowledge gap. Further confounding our understanding of transmission, αSyn aggregation appears able to propagate through glial networks as well. In a mouse line expressing αSyn only in oligodendrocytes, inoculation of neuronally-derived LB-αSyn extracts and oligodendrocyte-derived GCI-αSyn extracts in the thalamus resulted in spread of αSyn pathology to remote neuropils distant from the injection site, suggesting that αSyn aggregation can spread long distances solely through oligodendrocytes [236]. It is unclear if there are shared or distinct mechanisms of trans-glial vs trans-neuronal propagation. Other insights from rodent models Anatomical connectivity alone does not fully account for the pattern of αSyn propagation observed in vivo. Determinants of selective neuronal vulnerability are multifactorial and strongly influenced by age, genetics, and cell type. Aging markedly alters disease trajectory; young animals can mount compensatory responses, including pruning of vulnerable axonal terminals, thereby preserving function despite αSyn accumulation [196]. In contrast, aged mice exhibit impaired lysosomal and proteostatic capacity, resulting in persistent inclusion burden and more extensive propagation [196]. Genetic risk factors similarly modulate susceptibility and spread: increased SNCA dosage accelerates inclusion formation [74], GBA1 deficiency promotes a bidirectional pathogenic loop between glucocerebrosidase dysfunction and αSyn accumulation [250], and the G2019S LRRK2 mutation alters network-level transmission dynamics [33]. The αSyn A53T mutation is particularly illustrative, as it lowers the threshold for pathology to the extent that even injection of monomeric αSyn induces microglial activation, substantia nigra pars compacta (SNpc) dopaminergic neuron loss, and SNpc neurons with S129-phosphorylated αSyn aggregates at higher levels compared to WT mice [74]. This demonstrates how a pre-existing, disease-associated genetic context shapes vulnerability to seeding. Cell type-specific properties further refine propagation patterns. SNpc dopaminergic neurons consistently exhibit greater vulnerability than VTA neurons, implicating intrinsic features such as extensive axonal arborization, calcium homeostasis, and metabolic burden [14, 35, 54]. In addition to dopaminergic neurons, cholinergic and serotonergic neurons show preferential involvement in certain paradigms, and αSyn accumulation in dorsal raphe neurons produces synaptic dysfunction and circuit-level hypoconnectivity associated with affective phenotypes [62, 209]. Recent single-cell and spatial transcriptomic analyses of human PD tissue further support the concept of intrinsic molecular susceptibility, revealing that vulnerable neuronal populations showing αSyn aggregation are enriched for genes relating to oxidative stress responses, mitochondrial metabolism, and endo-lysosomal function, while relatively spared populations show transcriptional signatures consistent with enhanced proteostatic and stress-response capacity [50, 75, 76]. These approaches in post-mortem tissue and rodent models also identify glial state transitions and region-specific inflammatory signatures that correlate with pathological burden, reinforcing the idea that local cellular milieu shapes disease trajectory [49–52]. Deficits in proteostasis mechanisms, including the ubiquitin–proteasome system and autophagy-lysosomal pathways, reduce the capacity of cells to clear misfolded or aggregated proteins, allowing αSyn assemblies to accumulate and seed further aggregation [57–61]. There is also extensive evidence suggesting that mitochondrial dysfunction and oxidative stress further exacerbate this process by promoting protein misfolding and damaging cellular components, while also compromising cellular energy balance for protein quality control pathways [62, 68–73]. In parallel, inflammatory signaling and glial activation can create a pro-oxidant and proteostatic stress environment that enhances neuronal susceptibility to αSyn pathology [21, 74, 195]. Similarly, co-pathology with other neurodegenerative processes, such as the aggregation of tau and amyloid-β, can impact a wide range of cellular functions and affect the spread of αSyn pathology [243, 251–253]. Taken together, data from rodent models suggest that pathological propagation of αSyn aggregation is dictated by interactions between network architecture and age-, gene-, and cell state-specific factors that determine whether transmitted seeds are cleared, contained, or amplified into progressive pathology. Limitations of rodent models Mouse and rat models provide exquisite experimental control and the potential for mechanistic understanding, but they nonetheless have inherent limitations. PD is a decade-long, multifactorial, and age-dependent disorder, whereas rodent models compress disease trajectories into weeks or months. Despite genetic and anatomical conservation between mice, species differences in αSyn sequence constrain interpretation of findings from animal models towards human pathology: for instance, human PFFs are less efficient than mouse PFFs at inducing pathology in mice, suggesting that seeding potency and strain behavior depend on host factors [26, 207]. Similarly, studies using A53T transgenic lines demonstrate that monomeric αSyn can become pathogenic only under conditions of high basal expression or altered protein conformation [74] – conditions that may exaggerate human pathology or are only applicable to rare genetic causes of PD, such as SNCA mutations or triplications. Another caveat is the artificial initiation of pathology. Whether through high-titer PFF injections or viral vector overexpression, these paradigms bypass upstream disease triggers, focusing instead on downstream propagation dynamics, mainly of the inoculum itself. Yet, when used thoughtfully, rodent models offer robust internal controls and provide a living, interconnected system for studying progression of PD-like pathology. As such, they are excellent for interrogating the processes of uptake, seeding, and release, but less informative about the initial misfolding events in sporadic synucleinopathies. Non-human primate models Experiments in non-human primates (NHP) have recapitulated key insights from cellular and rodent models. Injection of either synthetic PFFs or patient-derived αSyn aggregates causes native αSyn to aggregate and the pathology to spread to neuroanatomically connected areas [254]. While the results of these studies broadly support the model of αSyn aggregation’s prion-like spread, the specific distribution of secondary structures that develop pathology are inconsistent across studies. This may be related to differences in the composition of the inoculum, endogenous αSyn structure [255], neuroanatomic differences across primate species, different timeframes of analysis, or reflect other unknown processes that modulate propagation. Circuit-based propagation Despite this variability, studies in NHPs suggest retrograde spread of αSyn pathology within the brain (Fig. 5): PFF or LB-derived αSyn extracts from PD patients injected into the striatum results in pathological αSyn aggregation in neuropils providing direct synaptic input, including neocortex, substantia nigra, amygdala, globus pallidus, and thalamus, mapping closely onto known nigrostriatal, corticostriatal, thalamostriatal afferent pathways and pallidal circuits [256, 257]. This observed distribution of αSyn aggregation suggests retrograde propagation of pathology.Fig. 5Neuroanatomic propagation of αSyn aggregation in non-human primate. Inoculations in different locations in the primate brain (indicated by asterisks) demonstrate both rostral-to-caudal (A) and caudal-to-rostral (B) propagation of αSyn aggregation. The specific patterns of spread are highly dependent on the site of inoculation, providing evidence for both retrograde and anterograde transmission Neuroanatomic propagation of αSyn aggregation in non-human primate. Inoculations in different locations in the primate brain (indicated by asterisks) demonstrate both rostral-to-caudal (A) and caudal-to-rostral (B) propagation of αSyn aggregation. The specific patterns of spread are highly dependent on the site of inoculation, providing evidence for both retrograde and anterograde transmission However, as in rodent models, there are examples of anterograde propagation as well. Injection of LB-enriched fractions from post-mortem PD brain samples into the striatum and substantia nigra of macaque monkeys leads to pathological spread both anterogradely and retrogradely along nigrostriatal pathways [27]. Similarly, marmosets inoculated with αSyn PFFs in the olfactory bulb developed pathology in the amygdala and substantia nigra [254], suggesting anterograde transmission (Fig. 5). Studies in NHPs have explored the spread of αSyn pathology from the periphery to the CNS, with mixed and conflicting results. Bidirectional spread between the brain and periphery was observed in baboon monkeys: enteric injections of LB extracts derived from PD patients induced nigrostriatal pathology and striatal injections induced descending enteric pathology [258]. However, the lack of evidence of αSyn pathology in the vagus nerve suggests an alternative route of transmission. Similarly gastric PFF injections in macaques failed to produce any CNS involvement even after one year, despite maintaining robust enteric pathology [240]. These findings contrast with the vagal highway hypothesis supported by rodent studies. Collectively, these NHP studies suggest that while αSyn propagation is fundamentally constrained by structural connectivity in the brain, body-first propagation from the gut may be significantly more restricted, variable, or reliant on non-vagal, or even non-neural, pathways in primates compared to rodents. αSyn aggregate structure impacts propagation Studies in NHPs have further revealed how αSyn strains, the specific structure of αSyn aggregates, shape propagation distribution and efficiency. Injection of different strains of αSyn aggregates into the putamen produces distinct propagation patterns: human-derived samples drive spread to the globus pallidus, fibril strain results in spread to the substantia nigra, and ribbon strain exhibits a less aggressive and anatomically distinct pattern of spread compared to fibril strain [259]. Unlike mice, NHPs develop comparable degeneration from both soluble and fibrillar aggregate fractions, suggesting species-dependent differences in susceptibility and raising the possibility that primate neurons are intrinsically more sensitive to early-stage or small aggregate species [260]. These observations further suggest the existence of distinct mechanisms of release and uptake for different αSyn aggregate conformations. However, as in rodent studies, it is difficult to differentiate differences in cellular transfer from differences in seed potency. Limitations of NHP models Compared to rodents, NHPs can interrogate the systemic spread of pathology in a manner more relevant to humans. Yet, despite these strengths, NHP models face practical and technical limitations. Genetic diversity, costs, and ethical concerns restrict the cohort size of NHP studies. This can limit the temporal resolution and reduce feasibility for high-throughput screening. Many tools, including antibodies, tracers, and viral vectors, remain optimized for rodents, reducing sensitivity in primate tissue. Because most αSyn measurements rely on postmortem histology, mechanistic insight into dynamic cell-to-cell events is limited. Yet, even with these challenges, NHP studies provide valuable contributions for validating insights generated from in vitro and rodent systems, especially for investigating age-related changes, primate-specific circuit architecture, and the full systemic landscape through which αSyn pathology may arise and propagate. Diagnostic and therapeutic implications Slowing or stopping the transcellular propagation of αSyn aggregation is a potentially powerful disease-modifying therapy for synucleinopathies. The study of αSyn aggregate propagation highlights several approaches that may help achieve this goal (Fig. 6).Fig. 6Therapeutic approaches targeting αSyn pathology propagation. Nodes for potential treatment interventions (red t-shaped lines, right column) include inhibiting release, intracellular trafficking, and uptake of αSyn aggregate seeds, neutralization of extracellular αSyn aggregates, and disrupting corruption of native αSyn. Left column (green) represents example proposed treatments intervening at the corresponding step in pathological transmission Therapeutic approaches targeting αSyn pathology propagation. Nodes for potential treatment interventions (red t-shaped lines, right column) include inhibiting release, intracellular trafficking, and uptake of αSyn aggregate seeds, neutralization of extracellular αSyn aggregates, and disrupting corruption of native αSyn. Left column (green) represents example proposed treatments intervening at the corresponding step in pathological transmission Intercepting extracellular αSyn seeds before they can initiate new rounds of pathology is an exciting approach that has received considerable attention in recent years. Synthetic antibodies directed against αSyn aggregates are being actively studied as a means of reducing the spread of αSyn-related pathology. The first incarnation of this therapy, Cinpanemab, did not ultimately show benefit [261]. Its successor, Prasinezumab, may slow motor deterioration and may be effective in rapidly progressive early PD [262, 263]. Additional trials assessing different antibody agents targeting αSyn aggregates have failed to show significant slowing of disease progression, including MEDI1341 [264], Lu AF82422 [265, 266], and ABBV‑0805/Exidavnemab [267]. These disappointing results may suggest that the intervention was introduced too late in the disease course. By the time patients present for medical care, αSyn pathology is often already widespread and neuronal loss substantial, potentially limiting the ability of these agents to meaningfully alter disease progression [1, 268]. However, their failure also highlights how little is understood regarding the mechanism of αSyn aggregation propagation and the need for further research in this area. There are also efforts to induce an active immune response to similarly intercept extracellular αSyn aggregates and thereby prevent pathological propagation. Peptide vaccines mimicking αSyn aggregate epitopes, such as UB-312 [269] and AFFITOPE PD01A (ACI-7104.056) [270, 271] appear to be safe and well tolerated and are progressing towards phase 2 trials. There has been significantly less progress in developing therapeutics that block cell-to-cell transfer by inhibiting uptake, axonal transport, or release of pathological αSyn aggregates. This is in part due to the ubiquitous expression and generalized function of these pathways. There are, however, several small molecules in pre-clinical development that target dynamin-mediated endocytosis [272], axonal transport [273], exosome production and release [274], and gap junction activity [275]. The above strategies focus on the core steps of spread and have clear mechanistic ties to propagation. However, insights from the study of the spread of αSyn pathology will be important for other therapeutic interventions as well. These include: (1) Directly interfering with αSyn aggregation. Several small molecules are under investigation for their ability to stabilize αSyn in benign conformations, prevent misfolding, or block oligomerization [276, 277], including anle138b [278, 279], NPT200-11 [280], Minzasolmin [281], SynuClean-D [282], and CLR01 [283]. (2) Enhancing clearance of intracellular αSyn aggregates. Proteolysis- and autophagy-targeting chimeras are designed to recognize misfolded or aggregated αSyn and target them for degradation [275, 284–290]. Several small molecules are under investigation for their ability to similarly enhance αSyn aggregate degradation [291, 292]. However, these approaches remain in the pre-clinical phase. (3) Modulating lysosomal activity, such as enhancing glucocerebrosidase activity [293, 294] or bolstering autophagic clearance [295–297], will reduce intracellular αSyn burden and release of seeds, thereby indirectly limiting propagation. (4) Anti-inflammatory interventions include microglial modulation and inhibition of inflammatory cascades. These approaches are primarily aimed at mitigating secondary neurotoxicity, which also enhance clearance of extracellular seeds and shape the microenvironment to be more or less vulnerable to spread [298–301]. (5) Stage-specific interventions, including supporting compensatory resilience in early stages and reducing oxidative stress in aged or genetically susceptible contexts [302, 303], which may influence not only neuronal vulnerability but also the efficiency with which pathology disseminates across circuits. (6) Prodromal detection and regionally targeted prevention in olfactory and gut-brain networks, which provides an opportunity to intervene before widespread propagation begins [304–306]. Gain of a cogent and detailed understanding of the mechanisms underlying release and uptake of αSyn aggregates will be critical to the success of these emerging treatment strategies. Conclusion Taken together, these complementary model systems provide insight into the cascade of events leading to propagation of toxic αSyn species. Integration of findings across paradigms and model systems highlights a consistent picture: αSyn pathology propagates through defined neural networks, shaped by neuroanatomic connectivity, intrinsic cellular conditions, protein conformation, and genetic context. Specific mechanisms that are well supported across models include endocytic uptake of extracellular seeds and vesicle-mediated secretion (including lysosomal exocytosis). Cellular systems provide mechanistic insight into uptake, seeding, and release, while animal models reveal how connectivity, neuronal subtype, and systemic factors determine the spatiotemporal pattern of propagation. Evidence from primates underscores the relevance of these findings to human disease, demonstrating circuit-specific spread, peripheral-central interactions, and long-term disease progression. Despite these advances, critical questions remain unresolved. The directionality of αSyn spread has been demonstrated in both retrograde and anterograde directions, but the most pathologically relevant direction is unclear. The degree to which transmission depends on synaptic versus extra-synaptic routes and the nature of the transmissible species, whether fibril or other oligomeric configuration, also remains unresolved. It is unknown whether a single mechanism mediates transfer of αSyn, or whether distinct mechanisms operate in different cell types, anatomical regions, and steps of propagation. Addressing these questions will require integrating high-resolution imaging, sensitive detection of varied αSyn species, unification of viral injection and PFF propagation protocols, and refined in vivo models that develop prodromal disease symptoms and capture the diversity of cellular and circuit contexts. Some progress has recently been made towards the development of transgenic marmosets that reveal prodromal symptoms [307], the ability to detect not only larger αSyn aggregates and Lewy bodies but also smaller αSyn oligomers [308], and unification of preparation of PFFs [309], but other critical questions remain unaddressed. Resolving these mechanistic uncertainties is critical for developing therapeutic strategies that not only inhibit αSyn aggregation but also block its pathological spread.